Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OKYO Pharma Limited
OKYO | US
1.59
USD-0.06
-3.64%
OKYO | US
About OKYO Pharma Limited
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2023
As of date
16/04/2026
Close
1.59
Open
1.65
High
1.65
Low
1.59
OKYO Pharma Limited a preclinical biopharmaceutical company engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201 a bovine adrenal medulla lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London the United Kingdom.
View LessOKYO | US
Risk
54.6
Sharpe
0.44
Luna's Score
45/100
Recommendation
Sell
Luna says (OKYO | US)
What's Working
Low Debt to Equity (< 0.25)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
56.1%1 month
54.6%3 months
79.3%6 months
91.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
14.11
Debt to equity
-1.08
Debt to assets
0.43
Ent. to EBITDA
-4.29
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-15.75M
MarketCap
53.80M
MarketCap(USD)
53.80M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-2.97K
Short ratio
5.77
Short perc.
0.86
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.25
Range1M
0.29
Range3M
1.44
Volumes: Market Activity
Rel. volume
0.53
Price X volume
87.48K
